Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.65
-1.4%
$24.85
$20.23
▼
$38.26
$2.17B2.232.02 million shs4.13 million shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$18.00
-0.4%
$19.61
$15.34
▼
$27.30
$2.90B1.081.53 million shs1.13 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$95.97
-0.5%
$114.04
$61.22
▼
$134.00
$11.00B0.922.37 million shs2.04 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$10.67
-9.7%
$16.16
$10.53
▼
$29.23
$9.45B-1.495.76 million shs13.15 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-1.38%-17.89%-12.02%-28.96%-6.22%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-0.44%-9.32%+2.21%-29.93%+3.63%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.55%-6.81%-21.23%-10.83%+36.01%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-9.73%-40.16%-27.07%-18.61%-37.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.65
-1.4%
$24.85
$20.23
▼
$38.26
$2.17B2.232.02 million shs4.13 million shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$18.00
-0.4%
$19.61
$15.34
▼
$27.30
$2.90B1.081.53 million shs1.13 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$95.97
-0.5%
$114.04
$61.22
▼
$134.00
$11.00B0.922.37 million shs2.04 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$10.67
-9.7%
$16.16
$10.53
▼
$29.23
$9.45B-1.495.76 million shs13.15 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-1.38%-17.89%-12.02%-28.96%-6.22%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-0.44%-9.32%+2.21%-29.93%+3.63%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.55%-6.81%-21.23%-10.83%+36.01%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-9.73%-40.16%-27.07%-18.61%-37.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.75
Moderate Buy$47.64130.68% Upside
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
2.82
Moderate Buy$35.7198.41% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.46
Hold$108.1812.72% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.61
Moderate Buy$28.38165.95% Upside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, SMMT, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetBuy$43.00 ➝ $42.00
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetEqual Weight$20.00 ➝ $18.00
11/15/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingBuy
11/13/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOverweight$42.00 ➝ $37.00
11/13/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Initiated CoverageOverweight$35.00
11/11/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
DowngradeOverweight ➝ Equal Weight$105.00 ➝ $109.00
11/11/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Boost Price TargetOutperform$30.00 ➝ $33.00
11/11/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
DowngradeStrong-Buy ➝ Hold
11/9/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
UpgradeBuy (B) ➝ Buy (B+)
11/6/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
DowngradeOutperform ➝ Hold$110.00 ➝ $117.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$139.74M15.29N/AN/A$9.20 per share2.24
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M8.73N/AN/A$5.78 per share3.11
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B7.83$4.74 per share20.23($0.48) per share-199.94
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$1.04N/AN/AN/A-73.04%-32.76%-25.80%N/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$512.54M-$1.73N/AN/AN/AN/A-54.94%-42.15%N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.9317.339.790.3626.93%751.81%23.84%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.07N/AN/AN/AN/A-138.82%-117.11%N/A

Latest DNLI, BEAM, SMMT, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$2.30$2.39+$0.09$2.01$491.63 million$492.97 million
11/3/2026Q3 2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.17-$1.28-$0.11-$1.28$8.75 million$0.31 million
11/3/2026Q3 2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.2709$0.37+$0.6409$0.37$12.67 million$17.78 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.11
13.01
13.00
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
0.01
6.21
5.94
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
3.88
3.60
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.99
5.99

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.80%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
9.70%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
81.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
540103.50 million99.56 millionOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
507160.29 million144.74 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423114.01 million111.16 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.76 million145.56 millionOptionable

Recent News About These Companies

Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
2 Cancer-Drug Developers Seeing Unusual Options Volume
Summit and Akeso shares plunge after FDA rejects ivonescimab
Breakfast News: Summit’s FDA Setback Isn’t the End
FDA rejects Summit Therapeutics BLA for ivonescimab in lung cancer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$20.65 -0.29 (-1.38%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$21.24 +0.59 (+2.88%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$18.00 -0.08 (-0.44%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$17.75 -0.25 (-1.41%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$95.97 -0.53 (-0.55%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$95.50 -0.47 (-0.49%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$10.67 -1.15 (-9.73%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$10.65 -0.02 (-0.20%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.